IS6858A - Trísólpýridín sem bólgueyðandi efni - Google Patents
Trísólpýridín sem bólgueyðandi efniInfo
- Publication number
- IS6858A IS6858A IS6858A IS6858A IS6858A IS 6858 A IS6858 A IS 6858A IS 6858 A IS6858 A IS 6858A IS 6858 A IS6858 A IS 6858A IS 6858 A IS6858 A IS 6858A
- Authority
- IS
- Iceland
- Prior art keywords
- trisol
- pyridine
- inflammatory agent
- inflammatory
- agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27484001P | 2001-03-09 | 2001-03-09 | |
PCT/IB2002/000424 WO2002072579A1 (en) | 2001-03-09 | 2002-02-08 | Triazolopyridines as anti-inflammatory agents |
Publications (1)
Publication Number | Publication Date |
---|---|
IS6858A true IS6858A (is) | 2003-06-23 |
Family
ID=23049813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6858A IS6858A (is) | 2001-03-09 | 2003-06-23 | Trísólpýridín sem bólgueyðandi efni |
Country Status (37)
Country | Link |
---|---|
US (1) | US6696464B2 (is) |
EP (1) | EP1370559B1 (is) |
JP (1) | JP4130774B2 (is) |
KR (1) | KR20030080087A (is) |
CN (1) | CN1496366A (is) |
AP (1) | AP2002002463A0 (is) |
AR (1) | AR036152A1 (is) |
AT (1) | ATE323701T1 (is) |
BG (1) | BG108133A (is) |
BR (1) | BR0207990A (is) |
CA (1) | CA2440222C (is) |
CR (1) | CR7013A (is) |
CZ (1) | CZ20032185A3 (is) |
DE (1) | DE60210755T2 (is) |
DO (1) | DOP2002000353A (is) |
EA (1) | EA200300864A1 (is) |
EC (1) | ECSP034762A (is) |
EE (1) | EE200300437A (is) |
ES (1) | ES2260415T3 (is) |
GT (1) | GT200200042A (is) |
HR (1) | HRP20030719A2 (is) |
HU (1) | HUP0303415A2 (is) |
IL (1) | IL156567A0 (is) |
IS (1) | IS6858A (is) |
MA (1) | MA26991A1 (is) |
MX (1) | MXPA03008144A (is) |
NO (1) | NO20033969L (is) |
NZ (1) | NZ526528A (is) |
OA (1) | OA12552A (is) |
PA (1) | PA8541001A1 (is) |
PE (1) | PE20030010A1 (is) |
PL (1) | PL363959A1 (is) |
SK (1) | SK10272003A3 (is) |
TN (1) | TNSN02022A1 (is) |
UY (1) | UY27199A1 (is) |
WO (1) | WO2002072579A1 (is) |
ZA (1) | ZA200304983B (is) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372206B1 (en) * | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
EP1854798A3 (en) * | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
EP1467979B1 (en) * | 2001-12-19 | 2008-08-13 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and analogs thereof modulators of nuclear hormone receptor function |
PT1474395E (pt) | 2002-02-12 | 2008-01-02 | Smithkline Beecham Corp | Derivados de nicotinamida úteis como inibidores de p38 |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
US7037923B2 (en) | 2002-08-30 | 2006-05-02 | Pfizer, Inc. | Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
US7012143B2 (en) | 2002-08-30 | 2006-03-14 | Dombroski Mark A | Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
US20040092547A1 (en) * | 2002-08-30 | 2004-05-13 | Pfizer Inc | Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
US6949652B2 (en) | 2002-08-30 | 2005-09-27 | Pfizer, Inc. | Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine |
JP2006508914A (ja) * | 2002-08-30 | 2006-03-16 | ファイザー・プロダクツ・インク | トリアゾロ−ピリジン製造のための新規な方法および中間体 |
PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
JP2006517580A (ja) * | 2003-02-14 | 2006-07-27 | ファイザー・プロダクツ・インク | 抗炎症化合物としてのトリアゾロピリジン |
CA2517517C (en) | 2003-03-03 | 2012-12-18 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
BRPI0417674A (pt) * | 2003-12-18 | 2007-03-20 | Pfizer Prod Inc | método para tratar a inflamação aguda em animais, com inibidores de quinase map p38 |
TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
MXPA06014637A (es) * | 2004-06-25 | 2007-02-12 | Amgen Inc | Triazoles e indazoles condensados utiles en el tratamiento de enfermedades mediadas por citocinas y otras enfermedades. |
PL1778686T3 (pl) | 2004-08-12 | 2009-04-30 | Pfizer | Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38 |
KR100871535B1 (ko) | 2004-08-12 | 2008-12-05 | 화이자 인코포레이티드 | P38 map 키나아제 억제제로서의트리아졸로피리딘일설판일 유도체 |
WO2006018727A2 (en) * | 2004-08-18 | 2006-02-23 | Pharmacia & Upjohn Company Llc | Triazolopyridine compounds useful for the treatment of inflammation |
CA2577478A1 (en) * | 2004-08-18 | 2006-02-23 | Pharmacia & Upjohn Company Llc | Triazolopyridine compounds |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
US7579360B2 (en) * | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US7572807B2 (en) * | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
PE20070341A1 (es) * | 2005-07-29 | 2007-04-13 | Wyeth Corp | Derivados de pirrol como moduladores del receptor de progesterona |
PE20070182A1 (es) | 2005-07-29 | 2007-03-06 | Wyeth Corp | Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona |
PE20070404A1 (es) * | 2005-07-29 | 2007-05-10 | Wyeth Corp | Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona |
EP1981851B1 (en) | 2006-01-31 | 2012-01-25 | Array Biopharma, Inc. | Kinase inhibitors and methods of use thereof |
CA2660836A1 (en) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
ES2301380B1 (es) | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
US7790741B2 (en) | 2006-10-06 | 2010-09-07 | Abbott Laboratories | Imidazothiazoles and imidazoxazoles |
EP2099447B1 (en) | 2006-11-22 | 2012-11-07 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
ES2329639B1 (es) | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
US8188083B2 (en) * | 2007-06-28 | 2012-05-29 | Abbott Laboratories | Triazolopyridazines |
WO2009027283A1 (en) * | 2007-08-31 | 2009-03-05 | Merck Serono S.A. | Triazolopyridine compounds and their use as ask inhibitors |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
WO2009143211A2 (en) | 2008-05-21 | 2009-11-26 | Incyte Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
US8987251B2 (en) | 2008-08-19 | 2015-03-24 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
US8895550B2 (en) | 2008-08-19 | 2014-11-25 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之三唑吡啶化合物 |
WO2011014462A1 (en) | 2009-07-27 | 2011-02-03 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
CN102812027B (zh) | 2010-02-03 | 2015-01-07 | 因西特公司 | 作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪 |
WO2012003392A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
CN103370316B (zh) * | 2010-11-16 | 2015-06-24 | 南京英派药业有限公司 | 作为细胞增殖抑制剂的3-芳基-6-芳基-[1,2,4]三唑并[4,3-a]吡啶及其应用 |
RU2598846C2 (ru) | 2011-02-25 | 2016-09-27 | Эррэй Биофарма Инк. | Триазолопиридиновые соединения как ингибиторы киназы pim |
CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
NO3175985T3 (is) | 2011-07-01 | 2018-04-28 | ||
TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
BR112015022488A2 (pt) * | 2013-03-14 | 2017-07-18 | Genentech Inc | triazolopiridinas substituídas e métodos de uso das mesmas |
GB201321742D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
AU2018346712B2 (en) | 2017-10-05 | 2021-04-01 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN116514801B (zh) * | 2022-01-20 | 2024-11-08 | 四川大学 | 2-苯基-[1,2,4]三唑并[1,5-a]吡啶类化合物、其氮氧化物及用途 |
CN114504636B (zh) * | 2022-01-27 | 2023-09-26 | 华南理工大学 | 一种杏仁油烫伤膏及其制备方法与应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US576499A (en) * | 1897-02-02 | Gas apparatus | ||
US5716972A (en) * | 1993-01-13 | 1998-02-10 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
DK0724588T3 (da) | 1993-09-17 | 2000-05-15 | Smithkline Beecham Corp | Lægemiddelbindende protein |
IT1269176B (it) * | 1994-01-11 | 1997-03-21 | Isagro Srl | Eterobicicli ad attivita' fungicida |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
ES2205167T3 (es) | 1996-01-11 | 2004-05-01 | Smithkline Beecham Corporation | Nuevos compuestos de imidazol sustituidos. |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
JP2002516325A (ja) | 1998-05-26 | 2002-06-04 | スミスクライン・ビーチャム・コーポレイション | 新規な置換イミダゾール化合物 |
US6207687B1 (en) * | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
US6350744B1 (en) | 1998-11-20 | 2002-02-26 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
JP4634613B2 (ja) | 1998-12-16 | 2011-02-16 | アベンティス・フアーマ・リミテッド | ヘテロアリール環状アセタール類 |
EP1140083A4 (en) | 1999-01-08 | 2004-01-02 | Smithkline Beecham Corp | NEW CONNECTIONS |
ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
CO5170501A1 (es) | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
-
2002
- 2002-02-08 AT AT02710260T patent/ATE323701T1/de not_active IP Right Cessation
- 2002-02-08 WO PCT/IB2002/000424 patent/WO2002072579A1/en active IP Right Grant
- 2002-02-08 IL IL15656702A patent/IL156567A0/xx unknown
- 2002-02-08 JP JP2002571495A patent/JP4130774B2/ja not_active Expired - Fee Related
- 2002-02-08 EA EA200300864A patent/EA200300864A1/ru unknown
- 2002-02-08 SK SK1027-2003A patent/SK10272003A3/sk unknown
- 2002-02-08 EP EP02710260A patent/EP1370559B1/en not_active Expired - Lifetime
- 2002-02-08 HU HU0303415A patent/HUP0303415A2/hu unknown
- 2002-02-08 AP APAP/P/2002/002463A patent/AP2002002463A0/en unknown
- 2002-02-08 MX MXPA03008144A patent/MXPA03008144A/es active IP Right Grant
- 2002-02-08 CN CNA028062825A patent/CN1496366A/zh active Pending
- 2002-02-08 KR KR10-2003-7011919A patent/KR20030080087A/ko not_active Application Discontinuation
- 2002-02-08 PL PL02363959A patent/PL363959A1/xx not_active Application Discontinuation
- 2002-02-08 CA CA002440222A patent/CA2440222C/en not_active Expired - Fee Related
- 2002-02-08 NZ NZ526528A patent/NZ526528A/en unknown
- 2002-02-08 OA OA1200300203A patent/OA12552A/en unknown
- 2002-02-08 DE DE60210755T patent/DE60210755T2/de not_active Expired - Fee Related
- 2002-02-08 CZ CZ20032185A patent/CZ20032185A3/cs unknown
- 2002-02-08 ES ES02710260T patent/ES2260415T3/es not_active Expired - Lifetime
- 2002-02-08 EE EEP200300437A patent/EE200300437A/xx unknown
- 2002-02-08 BR BR0207990-9A patent/BR0207990A/pt not_active IP Right Cessation
- 2002-03-05 GT GT200200042A patent/GT200200042A/es unknown
- 2002-03-06 DO DO2002000353A patent/DOP2002000353A/es unknown
- 2002-03-07 PE PE2002000182A patent/PE20030010A1/es not_active Application Discontinuation
- 2002-03-07 AR ARP020100826A patent/AR036152A1/es unknown
- 2002-03-07 UY UY27199A patent/UY27199A1/es not_active Application Discontinuation
- 2002-03-08 PA PA20028541001A patent/PA8541001A1/es unknown
- 2002-03-08 TN TNTNSN02022A patent/TNSN02022A1/fr unknown
- 2002-03-11 US US10/094,760 patent/US6696464B2/en not_active Expired - Fee Related
-
2003
- 2003-06-23 IS IS6858A patent/IS6858A/is unknown
- 2003-06-26 ZA ZA200304983A patent/ZA200304983B/en unknown
- 2003-06-30 CR CR7013A patent/CR7013A/es not_active Application Discontinuation
- 2003-08-07 MA MA27269A patent/MA26991A1/fr unknown
- 2003-08-25 BG BG108133A patent/BG108133A/bg unknown
- 2003-09-08 NO NO20033969A patent/NO20033969L/no not_active Application Discontinuation
- 2003-09-09 HR HR20030719A patent/HRP20030719A2/hr not_active Application Discontinuation
- 2003-09-09 EC EC2003004762A patent/ECSP034762A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS6858A (is) | Trísólpýridín sem bólgueyðandi efni | |
NO20024508D0 (no) | Bygningskomponenter av kompositt | |
DE60201775D1 (de) | Leistungsschalter | |
NO2008006I2 (no) | Fluticasone furoate | |
ATE319451T1 (de) | Tetrahydrochinolin-derivate | |
DE60223654D1 (de) | Resistzusammensetzung | |
FI20010780A0 (fi) | Parannetut koostumukset | |
IS6915A (is) | Lyfjablanda | |
ATE312827T1 (de) | 3-substituierte-4-pyrimidonderivate | |
NO20031869D0 (no) | Antiinflammatoriske midler | |
BR0210619A (pt) | composição | |
DE60212628D1 (de) | Nanopartikel-strukturen | |
FI20011300A0 (fi) | Sprinkleri | |
DE60223031D1 (de) | Arylpiperazin gebundene tetrahydroindolonderivate | |
DE60122834D1 (de) | Torsions-Kipp-Komponente | |
NO20031316D0 (no) | Beleggsammensetninger | |
DK1456482T3 (da) | Gipsplade | |
DE50105875D1 (de) | Bauteil | |
GB0122731D0 (en) | Anti-inflammatory agent | |
ITTO20020747A0 (it) | Composizione | |
ATA7722002A (de) | Kältemaschine | |
DE60202381D1 (de) | Paroxetin-n-formyl-derivate | |
DE50213834D1 (de) | Trennmittel | |
ITTO20020745A0 (it) | Composizione | |
DE50107699D1 (de) | Bauelement |